Literature DB >> 24828848

Intravenous dezocine pretreatment reduces the incidence and intensity of myoclonus induced by etomidate.

Zhifeng Lv, Zhifeng Lu1, Jie Fang, Jianpo Zhu, Bing Liang, Fangkun Li, Suli Jiang, Ali Li, Zhifang Cheng, Tieli Dong.   

Abstract

To evaluate the suppressive effect of intravenous dezocine on the incidence and severity of myoclonic movements induced by etomidate, a total of 80 patients, American Society of Anesthesiologists physical status I-II, were randomized into two equally sized groups (n = 40). These two groups were assigned to give either intravenous dezocine 0.1 mg/kg or a matching placebo (equal volume of 0.9% saline) 30 s before administration of etomidate. For anesthesia induction, 0.3 mg/kg etomidate was injected over a period of 1 min. One minute after etomidate administration, the severity of myoclonus was assessed. Pretreatment with dezocine significantly reduced both the incidence and intensity of myoclonus. These results demonstrate that intravenous dezocine 0.1 mg/kg 30 s prior to induction was effective in suppressing myoclonic movements in our patients.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24828848     DOI: 10.1007/s00540-014-1842-6

Source DB:  PubMed          Journal:  J Anesth        ISSN: 0913-8668            Impact factor:   2.078


  18 in total

1.  [Fentanyl in the prevention of etomidate-induced myoclonus].

Authors:  A Fassoulaki; C Pateras; P Kaniaris
Journal:  Cah Anesthesiol       Date:  1987 May-Jun

Review 2.  Dezocine. A preliminary review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy.

Authors:  J J O'Brien; P Benfield
Journal:  Drugs       Date:  1989-08       Impact factor: 9.546

3.  Pretreatment with dexmedetomidine or thiopental decreases myoclonus after etomidate: a randomized, double-blind controlled trial.

Authors:  Ayse Mizrak; Senem Koruk; Murat Bilgi; Betul Kocamer; Ibrahim Erkutlu; Suleyman Ganidagli; Unsal Oner
Journal:  J Surg Res       Date:  2009-08-19       Impact factor: 2.192

4.  [Anesthesia induction using etomidate in a lipid emulsion].

Authors:  P J Kulka; F Bremer; J Schüttler
Journal:  Anaesthesist       Date:  1993-04       Impact factor: 1.041

5.  Inhibition of adrenal steroidogenesis by the anesthetic etomidate.

Authors:  R L Wagner; P F White; P B Kan; M H Rosenthal; D Feldman
Journal:  N Engl J Med       Date:  1984-05-31       Impact factor: 91.245

6.  Low-dose intravenous midazolam reduces etomidate-induced myoclonus: a prospective, randomized study in patients undergoing elective cardioversion.

Authors:  Lars Hüter; Torsten Schreiber; Michael Gugel; Konrad Schwarzkopf
Journal:  Anesth Analg       Date:  2007-11       Impact factor: 5.108

7.  A comparison of two formulations for etomidate, 2-hydroxypropyl-beta-cyclodextrin (HPCD) and propylene glycol.

Authors:  A Doenicke; M F Roizen; A E Nebauer; A Kugler; R Hoernecke; H Beger-Hintzen
Journal:  Anesth Analg       Date:  1994-11       Impact factor: 5.108

8.  Pretreatment with sufentanil reduces myoclonus after etomidate.

Authors:  L Hueter; K Schwarzkopf; M Simon; D Bredle; H Fritz
Journal:  Acta Anaesthesiol Scand       Date:  2003-04       Impact factor: 2.105

9.  Reducing myoclonus after etomidate.

Authors:  A W Doenicke; M F Roizen; J Kugler; H Kroll; J Foss; P Ostwald
Journal:  Anesthesiology       Date:  1999-01       Impact factor: 7.892

10.  Prevention of etomidate-related myoclonus in anesthetic induction by pretreatment with magnesium.

Authors:  Bulent Un; Dilek Ceyhan; Birgul Yelken
Journal:  J Res Med Sci       Date:  2011-11       Impact factor: 1.852

View more
  10 in total

Review 1.  Dezocine as a potent analgesic: overview of its pharmacological characterization.

Authors:  Rong-Rong Ye; Shuang Jiang; Xu Xu; Yan Lu; Yu-Jun Wang; Jing-Gen Liu
Journal:  Acta Pharmacol Sin       Date:  2021-11-04       Impact factor: 7.169

2.  Effects of dezocine on PAED scale and Ramsay sedation scores in patients undergoing NUSS procedure.

Authors:  Yingjing Xia; Yingying Sun; Junxia Liu
Journal:  Am J Transl Res       Date:  2021-05-15       Impact factor: 4.060

3.  Comparison of the Effects of Low-Dose Midazolam, Magnesium Sulfate, Remifentanil and Low-Dose Etomidate on Prevention of Etomidate-Induced Myoclonus in Orthopedic Surgeries.

Authors:  Abbas Sedighinejad; Bahram Naderi Nabi; Mohammad Haghighi; Gelareh Biazar; Vali Imantalab; Siamak Rimaz; Zahra Zaridoost
Journal:  Anesth Pain Med       Date:  2016-04-02

4.  Oxycodone for prevention of etomidate-induced myoclonus: a randomized double-blind controlled trial.

Authors:  Wei Wang; Jie Lv; Qi Wang; Lei Yang; Wanyou Yu
Journal:  J Int Med Res       Date:  2018-03-14       Impact factor: 1.671

5.  Effect of Fentanyl and Nalbuphine for Prevention of Etomidate-Induced Myoclonus.

Authors:  Megha Bisht; Abhimanyu Singh Pokhriyal; Gurjeet Khurana; Jagdish P Sharma
Journal:  Anesth Essays Res       Date:  2019 Jan-Mar

6.  Pretreatment with Nalbuphine Prevents Sufentanil-Induced Cough During the Anesthesia Induction: A Randomized Controlled Trial.

Authors:  Jiang Wang; Jinjuan Duan; Qiuyue Wang; Yao Lu
Journal:  Ther Clin Risk Manag       Date:  2020-04-14       Impact factor: 2.423

7.  Comparison of the Effectiveness of Various Drug Interventions to Prevent Etomidate-Induced Myoclonus: A Bayesian Network Meta-Analysis.

Authors:  Kang-Da Zhang; Lin-Yu Wang; Dan-Xu Zhang; Zhi-Hua Zhang; Huan-Liang Wang
Journal:  Front Med (Lausanne)       Date:  2022-04-26

8.  Using dezocine to prevent etomidate-induced myoclonus: a meta-analysis of randomized trials.

Authors:  Yu Zhu; Yuting Yang; Chengmao Zhou; Zeqing Bao
Journal:  Drug Des Devel Ther       Date:  2017-07-18       Impact factor: 4.162

9.  Nalbuphine pretreatment for prevention of etomidate induced myoclonus: A prospective, randomized and double-blind study.

Authors:  Mayank Gupta; Priyanka Gupta
Journal:  J Anaesthesiol Clin Pharmacol       Date:  2018 Apr-Jun

Review 10.  Etomidate and its Analogs: A Review of Pharmacokinetics and Pharmacodynamics.

Authors:  Beatrijs I Valk; Michel M R F Struys
Journal:  Clin Pharmacokinet       Date:  2021-06-01       Impact factor: 6.447

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.